There was agreement that, although it was important to maximize the rapid sharing and adoption of resources/methods for patient-based disease studies, it was critical that this be balanced with the need for innovation at this early stage in the field. For example, although reprogramming technologies had advanced tremendously, some participants cautioned funding organizations to not restrict iPSC production to a single method or provider, since questions still remained about best practices. Additionally, analysis of specific biological processes or disorders may benefit from tailored cell derivation technologies (e.g., parthenogenesis), stem cell patterning (e.g., naive versus primed hiPSCs), and strategies for genetic manipulation (e.g., CRISPR-Cas9 versus TALEN).
